Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EMBC NASDAQ:EYE NASDAQ:LMAT NASDAQ:NVCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMBCEmbecta$9.96-2.0%$10.27$9.20▼$21.48$593.78M1.08522,700 shs673,486 shsEYENational Vision$24.21-0.2%$23.05$9.56▼$25.67$1.92B1.271.91 million shs1.81 million shsLMATLeMaitre Vascular$81.04-0.2%$82.52$71.42▼$109.58$1.84B0.82101,135 shs126,468 shsNVCRNovoCure$11.32-2.2%$16.61$10.91▼$34.13$1.29B0.611.70 million shs2.06 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMBCEmbecta-1.97%-15.09%-2.83%-21.76%-36.44%EYENational Vision-0.21%-3.24%+0.21%+84.25%+67.43%LMATLeMaitre Vascular-0.25%-1.69%-3.35%+2.97%-6.73%NVCRNovoCure-2.16%-5.98%-36.69%-37.63%-50.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMBCEmbecta4.6531 of 5 stars3.23.03.30.02.73.33.8EYENational Vision2.8286 of 5 stars2.32.00.03.33.40.80.0LMATLeMaitre Vascular2.9562 of 5 stars2.23.03.30.02.12.51.3NVCRNovoCure4.3914 of 5 stars3.35.00.04.52.43.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMBCEmbecta 2.33Hold$19.0090.76% UpsideEYENational Vision 2.60Moderate Buy$24.18-0.12% DownsideLMATLeMaitre Vascular 2.33Hold$97.8320.72% UpsideNVCRNovoCure 2.57Moderate Buy$28.79154.29% UpsideCurrent Analyst Ratings BreakdownLatest EMBC, NVCR, LMAT, and EYE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025EYENational VisionRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.007/25/2025NVCRNovoCureWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$40.00 ➝ $14.507/23/2025EYENational VisionWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $24.007/22/2025LMATLeMaitre VascularBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform7/16/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$13.00 ➝ $12.007/8/2025EYENational VisionUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.007/8/2025EYENational VisionNational BanksharesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$30.007/8/2025EYENational VisionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$17.00 ➝ $30.007/8/2025NVCRNovoCureLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/27/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.006/18/2025EYENational VisionBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.00(Data available from 8/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMBCEmbecta$1.08B0.54$3.27 per share3.05($12.80) per share-0.78EYENational Vision$1.82B1.05$1.63 per share14.83$10.37 per share2.33LMATLeMaitre Vascular$219.86M8.33$2.38 per share34.01$15.00 per share5.40NVCRNovoCure$605.22M2.09N/AN/A$3.13 per share3.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMBCEmbecta$78.30M$0.9011.073.240.654.89%-19.67%12.27%8/8/2025 (Estimated)EYENational Vision-$28.50M-$0.33N/A89.673.44-1.40%3.44%1.40%8/6/2025 (Estimated)LMATLeMaitre Vascular$44.04M$1.9840.9337.352.1419.96%13.53%9.78%8/5/2025 (Estimated)NVCRNovoCure-$168.63M-$1.56N/AN/AN/A-27.13%-47.74%-13.79%N/ALatest EMBC, NVCR, LMAT, and EYE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q3 2025EMBCEmbecta$0.7720N/AN/AN/A$278.15 millionN/A8/6/2025Q2 2025EYENational Vision$0.12N/AN/AN/A$469.21 millionN/A8/5/2025Q2 2025LMATLeMaitre Vascular$0.57N/AN/AN/A$62.48 millionN/A7/24/2025Q2 2025NVCRNovoCure-$0.39-$0.36+$0.03-$0.36$153.87 million$158.80 million5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/7/2025Q1 2025EYENational Vision$0.32$0.34+$0.02$0.18$510.30 million$510.32 million5/1/2025Q1 2025LMATLeMaitre Vascular$0.50$0.48-$0.02$0.48$57.61 million$59.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMBCEmbecta$0.606.02%N/A66.67%N/AEYENational VisionN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.99%N/A40.40%14 YearsNVCRNovoCureN/AN/AN/AN/AN/ALatest EMBC, NVCR, LMAT, and EYE DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMBCEmbectaN/A2.481.83EYENational Vision0.290.540.35LMATLeMaitre Vascular0.4816.4913.83NVCRNovoCure0.281.451.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMBCEmbecta93.83%EYENational VisionN/ALMATLeMaitre Vascular84.64%NVCRNovoCure84.61%Insider OwnershipCompanyInsider OwnershipEMBCEmbecta0.42%EYENational Vision2.70%LMATLeMaitre Vascular9.50%NVCRNovoCure5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMBCEmbecta2,10058.44 million58.20 millionOptionableEYENational Vision13,41179.05 million76.92 millionOptionableLMATLeMaitre Vascular49022.59 million20.45 millionOptionableNVCRNovoCure1,488111.80 million105.63 millionOptionableEMBC, EYE, LMAT, and NVCR HeadlinesRecent News About These CompaniesNovoCure (NASDAQ:NVCR) Trading Up 9.3% Following Insider Buying Activity49 minutes ago | americanbankingnews.comNovoCure (NASDAQ:NVCR) Trading 9.3% Higher on Insider Buying ActivityAugust 1 at 11:48 AM | marketbeat.comNovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain AheadAugust 1 at 2:16 AM | seekingalpha.comInsider Buying: NovoCure Limited (NASDAQ:NVCR) CFO Purchases 20,000 Shares of StockJuly 31 at 7:37 PM | marketbeat.comNovoCure (NASDAQ:NVCR) Hits New 52-Week Low - Time to Sell?July 31 at 12:22 PM | marketbeat.comChristoph Brackmann Buys 20,000 Shares of NovoCure Limited (NASDAQ:NVCR) StockJuly 31 at 6:37 AM | insidertrades.comNovoCure's Wearable Oncology Edge And Compelling ValuationJuly 30 at 2:04 AM | seekingalpha.comNovoCure Limited (NASDAQ:NVCR) Q2 2025 Earnings Call TranscriptJuly 29, 2025 | msn.comNovoCure's (NVCR) "Equal Weight" Rating Reiterated at Wells Fargo & CompanyJuly 28, 2025 | americanbankingnews.comBaillie Gifford & Co. Sells 24,330 Shares of NovoCure Limited (NASDAQ:NVCR)July 27, 2025 | marketbeat.comAnalysts Set NovoCure Limited (NASDAQ:NVCR) Target Price at $32.43July 27, 2025 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Trading Down 5.6% - Should You Sell?July 26, 2025 | marketbeat.comWells Fargo & Company Reaffirms Equal Weight Rating for NovoCure (NASDAQ:NVCR)July 26, 2025 | marketbeat.comWells Fargo Downgrades NovoCure (NVCR)July 26, 2025 | msn.comNovoCure Q2 Revenue Jumps 6 PercentJuly 25, 2025 | theglobeandmail.comNovoCure Limited (NVCR) Q2 2025 Earnings Call TranscriptJuly 25, 2025 | seekingalpha.comNovoCure Limited 2025 Q2 - Results - Earnings Call PresentationJuly 25, 2025 | seekingalpha.comNovoCure (NASDAQ:NVCR) Sets New 52-Week Low - Here's WhyJuly 25, 2025 | marketbeat.comNovocure: Steady Ahead of Key MilestonesJuly 24, 2025 | msn.comNovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to SayJuly 24, 2025 | zacks.comNovoCure (NVCR) Reports Q2 Loss, Tops Revenue EstimatesJuly 24, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines2025: A Pivotal Year for Smart Glasses As Meta Invests in Ray-BanBy Leo Miller | July 18, 2025View 2025: A Pivotal Year for Smart Glasses As Meta Invests in Ray-Ban3 Retail Stocks to Watch as Back-to-School Spending Ramps UpBy Chris Markoch | July 14, 2025View 3 Retail Stocks to Watch as Back-to-School Spending Ramps UpCrowdStrike Stock Eyes Next Move With AI in FocusBy Chris Markoch | July 29, 2025View CrowdStrike Stock Eyes Next Move With AI in FocusAES Gains 20% as Private Equity Eyes AI Hyperscale Energy PlayerBy Leo Miller | July 14, 2025View AES Gains 20% as Private Equity Eyes AI Hyperscale Energy PlayerAbbVie Stock Eyes Breakout as Pipeline and Profits GrowBy Chris Markoch | July 31, 2025View AbbVie Stock Eyes Breakout as Pipeline and Profits GrowEMBC, EYE, LMAT, and NVCR Company DescriptionsEmbecta NASDAQ:EMBC$9.96 -0.20 (-1.97%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.06 +0.10 (+1.00%) As of 08/1/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.National Vision NASDAQ:EYE$24.21 -0.05 (-0.21%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$24.20 -0.01 (-0.04%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.LeMaitre Vascular NASDAQ:LMAT$81.04 -0.20 (-0.25%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$81.10 +0.06 (+0.07%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.NovoCure NASDAQ:NVCR$11.32 -0.25 (-2.16%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.55 +0.23 (+2.02%) As of 08/1/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
